Diffuse large B-cell lymphoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Long-term Extension Study of PCI-32765 (Ibrutinib)

  NCT01804686· Janssen Research & Development, LLC· Source

• A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· Merck Sharp & Dohme LLC· Source

• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  NCT05139017· Merck Sharp & Dohme LLC· Source

• Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  NCT06395103· Merck Sharp & Dohme LLC· Source

• A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

  NCT05954910· Hoffmann-La Roche· Source

• A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

  NCT06765317· Memorial Sloan Kettering Cancer Center· Source

• Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

  NCT05952024· AstraZeneca· Source

• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  NCT03223610· National Cancer Institute (NCI)· Source

• Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas

  NCT07387848· American University of Beirut Medical Center· Source

• Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

  NCT03226704· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Gene Expression Profiling 1
• Whole Genome Sequencing 1
• Flow Cytometry 3
• Immunohistochemistry 2
• Xenograft Model Antitumor Assays 5
• Magnetic Resonance Imaging 1
• Machine Learning 1
• Cohort Studies 5

See which targets of this disease your abstract mentions, and go to the people working on them.